Sources | Names Used |
---|---|
CTRPv2 | doxorubicin:navitoclax (2:1 mol/mol) |
PharmacoGx | doxorubicin:navitoclax (2:1 mol/mol) |
Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | PDZD4 | CTRPv2 | pan-cancer | AAC | 0.2 | 5e-08 |
mRNA | CCP110 | CTRPv2 | pan-cancer | AAC | 0.18 | 5e-08 |
mRNA | NABP1 | CTRPv2 | pan-cancer | AAC | -0.18 | 6e-08 |
mRNA | SCAF4 | CTRPv2 | pan-cancer | AAC | 0.2 | 6e-08 |
mRNA | HSF2 | CTRPv2 | pan-cancer | AAC | 0.18 | 6e-08 |
mRNA | RAB39A | CTRPv2 | pan-cancer | AAC | 0.19 | 6e-08 |
mRNA | ANXA5 | CTRPv2 | pan-cancer | AAC | -0.24 | 6e-08 |
mRNA | HNRNPDL | CTRPv2 | pan-cancer | AAC | 0.2 | 7e-08 |
mRNA | ZNF124 | CTRPv2 | pan-cancer | AAC | 0.19 | 7e-08 |
mRNA | REV3L | CTRPv2 | pan-cancer | AAC | 0.18 | 7e-08 |